Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts

Atsunori Nakao, Chien Sheng Huang, Donna B. Stolz, Yinna Wang, Jonathan M. Franks, Naobumi Tochigi, Timothy R. Billiar, Yoshiya Toyoda, Edith Tzeng, Kenneth R. McCurry

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

AimsVeins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. Methods and resultsThe inferior vena cava was excised from donor rats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100 CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 36 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. ConclusionEx vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.

Original languageEnglish
Pages (from-to)457-463
Number of pages7
JournalCardiovascular Research
Volume89
Issue number2
DOIs
Publication statusPublished - Feb 1 2011
Externally publishedYes

Fingerprint

Tunica Intima
Carbon Monoxide
Hyperplasia
Veins
Transplants
Vascular Endothelial Growth Factor A
Hypoxia-Inducible Factor 1
Endothelial Cells
Neointima
Cell Aggregation
Abdominal Aorta
Inferior Vena Cava
Electron Microscopy
Leukocytes
Blood Platelets
Apoptosis

Keywords

  • Carbon monoxide
  • Hypoxia inducible factor
  • Intimal hyperplasia
  • Vascular endothelial growth factor
  • Vein graft

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Nakao, A., Huang, C. S., Stolz, D. B., Wang, Y., Franks, J. M., Tochigi, N., ... McCurry, K. R. (2011). Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. Cardiovascular Research, 89(2), 457-463. https://doi.org/10.1093/cvr/cvq298

Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. / Nakao, Atsunori; Huang, Chien Sheng; Stolz, Donna B.; Wang, Yinna; Franks, Jonathan M.; Tochigi, Naobumi; Billiar, Timothy R.; Toyoda, Yoshiya; Tzeng, Edith; McCurry, Kenneth R.

In: Cardiovascular Research, Vol. 89, No. 2, 01.02.2011, p. 457-463.

Research output: Contribution to journalArticle

Nakao, A, Huang, CS, Stolz, DB, Wang, Y, Franks, JM, Tochigi, N, Billiar, TR, Toyoda, Y, Tzeng, E & McCurry, KR 2011, 'Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts', Cardiovascular Research, vol. 89, no. 2, pp. 457-463. https://doi.org/10.1093/cvr/cvq298
Nakao, Atsunori ; Huang, Chien Sheng ; Stolz, Donna B. ; Wang, Yinna ; Franks, Jonathan M. ; Tochigi, Naobumi ; Billiar, Timothy R. ; Toyoda, Yoshiya ; Tzeng, Edith ; McCurry, Kenneth R. / Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. In: Cardiovascular Research. 2011 ; Vol. 89, No. 2. pp. 457-463.
@article{cf1505d3cac74394bd4c5a329576eab2,
title = "Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts",
abstract = "AimsVeins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. Methods and resultsThe inferior vena cava was excised from donor rats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100 CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 36 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. ConclusionEx vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.",
keywords = "Carbon monoxide, Hypoxia inducible factor, Intimal hyperplasia, Vascular endothelial growth factor, Vein graft",
author = "Atsunori Nakao and Huang, {Chien Sheng} and Stolz, {Donna B.} and Yinna Wang and Franks, {Jonathan M.} and Naobumi Tochigi and Billiar, {Timothy R.} and Yoshiya Toyoda and Edith Tzeng and McCurry, {Kenneth R.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1093/cvr/cvq298",
language = "English",
volume = "89",
pages = "457--463",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts

AU - Nakao, Atsunori

AU - Huang, Chien Sheng

AU - Stolz, Donna B.

AU - Wang, Yinna

AU - Franks, Jonathan M.

AU - Tochigi, Naobumi

AU - Billiar, Timothy R.

AU - Toyoda, Yoshiya

AU - Tzeng, Edith

AU - McCurry, Kenneth R.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - AimsVeins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. Methods and resultsThe inferior vena cava was excised from donor rats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100 CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 36 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. ConclusionEx vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.

AB - AimsVeins are still the best conduits available for arterial bypass surgery. When these arterialized vein grafts fail, it is often due to the development of intimal hyperplasia (IH). We investigated the feasibility and efficacy of the ex vivo pre-treatment of vein grafts with soluble carbon monoxide (CO) in the inhibition of IH. Methods and resultsThe inferior vena cava was excised from donor rats and placed as an interposition graft into the abdominal aorta of syngeneic rats. Prior to implantation, vein grafts were stored in cold Lactated Ringer (LR) solution with or without CO saturation (bubbling of 100 CO) for 2 h. Three and 6 weeks following grafting, vein grafts treated with cold LR for 2 h developed IH, whereas grafts implanted immediately after harvest demonstrated significantly less IH. Treatment in CO-saturated LR significantly inhibited IH and reduced vascular endothelial cell (VEC) apoptosis. Electron microscopy revealed improved VEC integrity with less platelet/white blood cell aggregation in CO-treated grafts. The effects of CO in preventing IH were associated with activation of hypoxia inducible factor-1α (HIF-1α) and an increase in vascular endothelial growth factor (VEGF) expression at 36 h after grafting. Treatment with a HIF-1α inhibitor completely abrogated the induction of VEGF by CO and reversed the protective effects of CO on prevention of IH. ConclusionEx vivo treatment of vein grafts in CO-saturated LR preserved VEC integrity perioperatively and significantly reduced neointima formation. These effects appear to be mediated through the activation of the HIF1α/VEGF pathway.

KW - Carbon monoxide

KW - Hypoxia inducible factor

KW - Intimal hyperplasia

KW - Vascular endothelial growth factor

KW - Vein graft

UR - http://www.scopus.com/inward/record.url?scp=78751517868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751517868&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvq298

DO - 10.1093/cvr/cvq298

M3 - Article

C2 - 20851811

AN - SCOPUS:78751517868

VL - 89

SP - 457

EP - 463

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 2

ER -